Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Mutation detection kit helps assess tumour mutation status before treatment

DxS : 26 October, 2007  (New Product)
Amgen has selected the DxS K-RAS Cancer Mutation Detection Kit to analyse patient samples from the pivotal 408’ study.
The study examines Vectibix versus best supportive care in patients with metastatic colorectal cancer who have progressed after all available chemotherapy regimens.

The drug has now received a recommendation from the European Committee for Medicinal Products for Human Use for conditional marketing authorisation from the European Medicines Agency for treating patients with refractory metastatic colorectal cancer whose tumours do not have a mutation of K-RAS.

At ECCO 14 - the European Cancer Conference Amgen presented 'Analysis of K-RAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy', which involved use of the DxS K-RAS Cancer Mutation Detection Kit. The study concludes that the efficacy of panitumumab monotherapy in metastatic colorectal cancer seems confined to patients with non-mutated K-RAS.

The test utilised is highly selective and robust, detecting seven key mutations in the K-RAS gene. DxS assays employ a real-time PCR format combining Scorpions and ARMS (allele specific PCR) technologies. The assays can detect less than one percent of mutant in a background of wild type genomic DNA and have a limit of detection of 10 copies or below.

The un-paralleled sensitivity of the technology means that the kit detects mutations frequently missed by sequencing methods. DxS is currently in discussion with regulatory authorities and service providers to ensure that an approved diagnostic is available to support the launch of Vectibix.

Commenting on the data, Dr Stephen Little the CEO of DxS said, 'We are very pleased that Amgen chose the DxS K-RAS mutation kit and have benefited from the excellent selectivity of the test to maximise the number of mutation positive individuals correctly identified in the analysis of tumour samples from the Vectibix pivotal study. K-RAS genotyping of tumours should now be considered in patients with metastatic colorectal cancer being treated with or considered for Vectibix monotherapy.'

Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo